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(anti-VEGF) were estimated based on prices established by Brazilian Drug Market 
Regulation Chamber. RESULTS: Nine studies were included: eight SR and one 
HTA. All reviews showed weak strength of recommendation and moderate to 
high quality of evidence. Sorafenib showed a median progression free-survival 
time around 6 months and was more effective than placebo, equally effective 
than interferon, and less effective than sunitinib. Patients who received 
sorafenib had a higher risk of suffering major adverse events. The cost of 
monthly treatment with anti-VEGF: sorafenib, sunitinib, temsirolimus, 
bevacizumab and interferon alpha was US$ 4.090,40, US$ 7.017,83, US$ 4.619,26, 
US$ 8.037,17 and US$ 3.166,67, respectively. CONCLUSIONS: Based on the 
available evidence, the increased survival caused by anti-VEGF is modest and 
based on weak evidence level, therefore with little clinical value. In addition, 
treatment with anti-VEGF is associated with serious adverse events and shows 
high cost. Hence we recommend the use of these drugs only when the surgical 
procedure isn’t indicated. All studies include patients with mCCR of clear cell, so 
it´s unclear whether the results can be extrapolated to patients with other stages 
and subtypes of RCC.  
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OBJECTIVES: Organized, nationwide screening for breast cancer with 
mammography started in Hungary in January 2002. Women in the age group  
45-65 years are the target population and 2 years screening interval is applied. 
The aim of this study is to evaluate the quality indicators of the 3rd screening 
round (2006-2007). METHODS: The data derive from the financial database of the 
National Health Insurance Fund Administration (NHIFA) covering the period of 
2006-2007. We calculated the following indicators: recall rate of women who 
underwent mammography examinations, attendance of re-called women, 
proportion of women referred to surgery, proportion of women who underwent 
surgery compared to referred women, proportion of benign and malign cases. 
RESULTS: In 2006-2007 there were 453142 screening mammography 
examinations in Hungary. 5.48% of participating women were re-called. The 
attendance of re-called women was 92.6%. Altogether 2087 women (9.6%) were 
referred for breast surgery but only 1503 women (72.0%) underwent surgery. 
Histological examination confirmed 379 benign (25.2%) and 1124 malign (74.8%) 
cases. CONCLUSIONS: The quality indicators of the Hungarian organized 
mammography screening program met the recommendations of international 
professional guidelines. However, in addition to current indicators, new ones 
should be introduced in order to provide a more comprehensive monitoring of 
the program.  
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OBJECTIVES: Organized, nationwide screening for breast cancer with 
mammography started in Hungary in January 2002. Women in the age group 45-
65 years are the target population and 2 years screening interval is applied. The 
aim of this study is to analyze the attendance rate of the 3rd screening round 
(2006-2007). METHODS: The data derive from the financial database of the 
National Health Insurance Fund Administration (NHIFA) covering the period of 
2006-2007. We calculated two attendance indicators. The up-take of the program 
means the percentage of women aged 45-65 who, having been sent an invitation 
for screening, attend a screening unit and undergo mammography in response 
to that invitation. We defined coverage as the ratio of women in the age group 
45-65 years having either a screening mammography or a diagnostic 
mammography. RESULTS: In 2006-2007 there were 453142 screening 
mammography cases and 1248183 diagnostic mammography examinations in 
Hungary. We found 41.7% and 52.5% up-take in 2006 and 2007 respectively; and 
46.3% combined rate for 2006/2007. The screening coverage was 29.2% and the 
diagnostic coverage was 21.6%, while the total coverage (screening and 
diagnostic) was 49.3%. CONCLUSIONS: The attendance of the Hungarian 
organized breast cancer screening program – compared to the previous period 
before the implementation of the organized screening program – is promising, 
although to achieve the expected results in mortality decrease a further 
improvement of both the uptake and coverage is necessary.  
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OBJECTIVES: To examine the impact of palonosetron versus other 5-HT3 RAs on 
incidence of delayed CINV at cycle 1 based on presence of certain risk factors 
(age <50 years, female gender, prior CINV, anxiety, no or minimal alcohol use, 
history of motion sickness, and emetogenicity of chemotherapy). METHODS: A 
retrospective claims analysis was conducted using OptumInsight database from 
December 1, 2005 to June 30, 2011. Continuously enrolled cancer patients >18 
years of age initiated on their first chemotherapy (index date) were included. 
Patients with a previous cancer diagnosis in the pre-index period or receiving 
multi-day chemotherapy were excluded. The study population was examined for 
differences in CINV rates by each 5-HT3 RA stratified by number of risk factors 
(female gender, age <50, previous anxiety, vomiting pre-index, and highly 
emetogenic chemotherapy. CINV was identified using ICD9CM codes for nausea, 
vomiting, or related events, and rescue medication use within 5 days after 
chemotherapy. RESULTS: Final analysis included 26,974 patients. Overall the 
percentage of patients experiencing CINV increased as the number of risk factors 
increased – 13.5%, 14.9%, 15.6%, and 18.4% for 0, 1, 2, and 3 or more risk factors, 
respectively. High-risk patients (3 or more risk factors) receiving palonosetron 
had less CINV events compared to ondansetron, granisetron, and dolasetron. 
Odds Ratios (OR) 95%CI versus palonosetron were 1.523 (1.231, 1.883), 1.426 
(1.146, 1.773), and 1.683 (1.271, 2.229), respectively. CONCLUSIONS: The 
probability of a CINV event increased with the accumulation of identified risk 
factors. Palonosetron demonstrated a statistically significant OR versus all other 
5-HT3 RA in patients at the highest risk of developing a CINV event.  
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OBJECTIVES: BTZ is administered for a finite course; thus, MM pts may remain 
sensitive to BTZ-based therapy at relapse. We conducted a meta-analysis to 
assess efficacy and safety of BTZ-based retreatment in studies of pts with 
relapsed (rel) and/or refractory (ref) MM. METHODS: The proportion of BTZ-ref 
pts was identified where available. Other prognostic factors were extracted and 
used in weighted stratified analyses of TTP, PFS, and OS. Random-effect pooled 
estimates were calculated for ORR (≥PR) and rates of common AEs. RESULTS: 
Twenty-three studies (N=1051 pts) were identified. BTZ was given IV in all 
studies. Retreatment comprised BTZ±dex in 4 studies and BTZ-based 
combination therapy in 19. BTZ-ref pts were included in 11 studies; 6 studies 
included only rel pts. Across studies with data available, pooled, weighted 
average ORR was 39% (95% CI: 31–47) and median TTP, PFS, and OS were 7.5, 5.8, 
and 16.6 months. Stratified univariate analyses showed outcomes were generally 
consistent across groups while pts with ≤4 prior therapies and rel (but not ref) 
pts had higher ORRs of 43% and 57%, respectively. By random-effects meta-
regression analysis, compared to ref pts, rel pts were associated with a higher 
ORR by 28–41 percentage points. The most common grade 3/4 AEs were 
thrombocytopenia (35%), neutropenia (15%), anemia (14%), pneumonia (10%), and 
peripheral neuropathy (3%). CONCLUSIONS: Based on these findings, BTZ 
retreatment is efficacious and well tolerated in rel pts. In an era of new and 
emerging treatment options, these data indicate BTZ retreatment continues to 
be a highly effective option in previously treated pts.  
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BACKGROUND: Prior to the March 25, 2011 FDA-approval of ipilimumab (ipi), 
clinical trial data indicated that no drug treatment (tx) for advanced melanoma 
(AM) (unresectable or metastatic melanoma) led to an improvement in overall 
survival (OS). OBJECTIVES: To further explore the relationship between OS and 
the treatments available for AM patients prior to ipi approval by examining real 
world (RM) data. METHODS: Baseline characteristics, tx and outcomes of 752 
newly diagnosed AM pts (2004-2008) were collected from the medical charts of a 
nationally representative random sample of 113 U.S. oncologists. Follow-up of 
survival outcomes concluded on the date of ipi approval. OS from AM diagnosis 
to 1 and 2 years were described by stage and by whether pts were incident (no 
prior melanoma) or recurrent (AM diagnosis after early-stage melanoma). To 
determine change in outcomes over time, current OS of incident pts was 
compared to published data on a prior cohort of pts from the AJCC registry, 
staged at initial melanoma diagnosis (Balch 2001). RESULTS: One-year (39.8%, 
95% CI=[34.2-45.3%]) and 2-year (27.6%, 95% CI=[22.4-32.8%]) survival rates among 
incident Stage IV pts were statistically similar to weighted averages (by 
metastasis classification) from the AJCC registry. Incident unresectable Stage III 
pts had lower OS rates than the weighted average of all Stage III pts from the 
AJCC registry (which included both resectable and unresectable pts). 
CONCLUSIONS: These real-world data show that incident metastatic melanoma 
pts diagnosed from 2004 to 2008 had OS similar to the AJCC registry pts—who 
were diagnosed in prior decades—and confirm the limitations of AM tx prior to 
ipi approval. Future research should examine OS in real-world AM pts following 
ipi approval.  
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OBJECTIVES: Colon cancer (CC) is primarily a disease of older individuals, with 
65.3% of incident cases in the United States occurring in those aged 65 and 
